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Background Black and Hispanic children living in urban environments in the USA have an excess burden of morbidity
and mortality from asthma. Therapies directed at the eosinophilic phenotype reduce asthma exacerbations in adults,
but few data are available in children and diverse populations. Furthermore, the molecular mechanisms that underlie
exacerbations either being prevented by, or persisting despite, immune-based therapies are not well understood. We
aimed to determine whether mepolizumab, added to guidelines-based care, reduced the number of asthma
exacerbations during a 52-week period compared with guidelines-based care alone.
Methods This is a randomised, double-blind, placebo-controlled, parallel-group trial done at nine urban medical
centres in the USA. Children and adolescents aged 6–17 years, who lived in socioeconomically disadvantaged
neighbourhoods and had exacerbation-prone asthma (defined as ≥two exacerbations in the previous year) and blood
eosinophils of at least 150 cells per µL were randomly assigned 1:1 to mepolizumab (6–11 years: 40 mg; 12–17 years:
100 mg) or placebo injections once every 4 weeks, plus guideline-based care, for 52 weeks. Randomisation was done
using a validated automated system. Participants, investigators, and the research staff who collected outcome
measures remained masked to group assignments. The primary outcome was the number of asthma exacerbations
that were treated with systemic corticosteroids during 52 weeks in the intention-to-treat population. The mechanisms
of treatment response were assessed by study investigators using nasal transcriptomic modular analysis. Safety was
assessed in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, NCT03292588.
Findings Between Nov 1, 2017, and Mar 12, 2020, we recruited 585 children and adolescents. We screened
390 individuals, of whom 335 met the inclusion criteria and were enrolled. 290 met the randomisation criteria, were
randomly assigned to mepolizumab (n=146) or placebo (n=144), and were included in the intention-to-treat analysis.
248 completed the study. The mean number of asthma exacerbations within the 52-week study period was
0·96 (95% CI 0·78–1·17) with mepolizumab and 1·30 (1·08–1·57) with placebo (rate ratio 0·73; 0·56–0·96; p=0·027).
Treatment-emergent adverse events occurred in 42 (29%) of 146 participants in the mepolizumab group versus
16 (11%) of 144 participants in the placebo group. No deaths were attributed to mepolizumab.
Interpretation Phenotype-directed therapy with mepolizumab in urban children with exacerbation-prone eosinophilic
asthma reduced the number of exacerbations.
Funding US National Institute of Allergy and Infectious Diseases and GlaxoSmithKline.
Copyright © 2022 Elsevier Ltd. All rights reserved.

Introduction
Asthma exacerbations are common events, particularly
in school-age children living in socioeconomically
disadvantaged urban neighbourhoods,1 and have
important short-term and long-term sequelae.2–4
Although conventional therapies, such as daily inhaled
corticosteroids with or without long-acting β agonists,
often improve asthma control, a substantial proportion
of children and adolescents have asthma that remains
inadequately controlled and at serious risk of
exacerbations.5,6 The identification of strategies to

prevent asthma exacerbations remains an important
unmet need, particularly for underserved urban Black
and Hispanic children with exacerbation-prone disease.7
The emergence of biologic therapies for asthma
provided opportunities for phenotype-directed approaches
to asthma management. Elevated concentrations of
eosinophils in the blood8,9 and airway10 have been identified
as biomarkers for increased risk of asthma exacerbation.
Targeted therapy with mepolizumab, a humanised
monoclonal antibody directed at interleukin (IL)-5,
significantly reduces exacerbations in adults with severe,
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Research in context
Evidence before this study
Black and Hispanic children living in urban environments in
the USA have an excess burden of morbidity and mortality from
asthma. Phenotype-directed biologic therapies for eosinophilic
asthma have revolutionised treatment for adults with severe
disease, but data are scarce in children and diverse populations.
Furthermore, precision biomarkers for responsiveness to these
therapies are needed.
Added value of this study
Therapy targeting eosinophils in urban children and adolescents
living in disadvantaged neighbourhoods significantly reduced
the number of asthma exacerbations, albeit to a lesser extent
than observed previously in adults, but did not affect other
asthma outcomes. Uniquely, we used airway transcriptomic
analyses to identify inflammatory pathways underlying
differential responses to mepolizumab therapy in these

exacerbation-prone asthma and blood eosinophils of 150
or more cells per µL.11,12 However, data in children,
adolescents, and racially and ethnically diverse populations
are scarce.7,13,14
Despite the use of targeted biologic therapies,
exacerbations continue to occur, albeit at reduced rates,
and the mechanisms underlying these variable treatment
responses have not been established. Although
mepolizumab markedly depletes blood eosinophils, the
relative change in blood eosinophils is not associated with
treatment efficacy and more precise biomarkers that
predict response have not been determined. Patterns of
inflammation in the airway could explain asthma
mechanisms with greater detail and serve as increasingly
precise biomarkers for treatment respon
siveness.
Transcriptome profiling allows for an unbiased
assessment of these inflammatory patterns. We previously
identified15 upper airway transcriptome modules, which
are networks of co-expressed and functionally related
genes, associated with asthma exacerbations in urban
children, and hypothesised that mepolizumab would
reduce exacerbations through suppression of eosinophilassociated airway transcript
ome modules. We further
hypothesised that airway transcriptome profiling would
identify alternative mechanisms associated with reduced
responses to therapy.
To address these gaps in asthma care and to gain
insight into mepolizumab’s clinical and mechanistic
effects,16 we did this Mechanisms Underlying Asthma
Exacerbations Prevented and Persistent with Immune
Based Therapy: a Systems Approach Phase 2
(MUPPITS-2) randomised controlled trial to assess the
efficacy, safety, and mechanisms of phenotype-directed
therapy with mepoli
zumab added to guidelines-based
care for urban children with exacerbation-prone
eosinophilic asthma.

children. We identified multiple inflammatory pathways
associated with eosinophils and the epithelium as drivers of
differential exacerbation risk in placebo and mepolizumab
treated participants.
Implications of all the available evidence
These findings highlight the importance of well powered
paediatric clinical trials to evaluate treatment responses for
biologics and other interventions that were evaluated initially
in adults. Furthermore, it is essential to evaluate treatment
responses in Black and Hispanic individuals, who are at the
greatest risk of morbidity and mortality from asthma and are
often under-represented in clinical trials. Finally, airway
transcriptomic profiling provides detailed molecular insights
into treatment response and non-response, thereby identifying
essential novel biomarkers and disease mechanisms.

Methods

Study design
The MUPPITS-2 study is a randomised, double-blind,
placebo-controlled, parallel-group trial done at nine urban
medical centres in the USA. The study was approved by the
Western Institutional Review Board. The protocol is in the
appendix (pp 20–97).

Participants
To identify potential participants, research staff used
methods approved by the independent review board,
including hospital admission records, clinicians’ specialtyclinic records, and local advertising campaigns. Research
staff screened potential participants using a standardised
recruitment questionnaire. Inclusion criteria included
children and adolescents (aged 6–17 years) with
exacerbation-prone asthma and blood eosinophils of 150
or more cells per µL who lived in prespecified low-income
US census tracts, had been diagnosed by a medical doctor
as having had asthma for at least 1 year, had two or more
exacerbations treated with systemic corticosteroids in the
previous year, required a minimum inhaled corticosteroids
regimen of twice-daily treatment with fluticasone
propionate 250 µg or equivalent (ages 6–11 years) or
fluticasone 250 µg plus salmeterol 50 µg or equivalent
(ages 12–17 years), had been vaccinated for chickenpox,
and had documentation of current medical insurance
with prescription coverage at the time of randomisation.
Exclusion criteria included pregnancy or lactation,
smoking, a life-threatening asthma exacerbation in the
past 2 years that required intubation, mechanical
ventilation, or resulted in a hypoxic seizure, and specified
medical conditions and treatments (appendix pp 43–44).
Parents provided written informed consent and children
aged 12–17 years provided written assent and children
aged 7–11 years provided verbal assent.
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Randomisation and masking
Randomisation was done using a validated automated
system at the US National Institute of Allergy and
Infectious Diseases (NIAID), Division of Allergy,
Immunology and Transplantation Statistical and Clinical
Coordinating Center (Rho, Durham, NC, USA).
Participants were randomly assigned to mepolizumab or
placebo, by a covariate adaptive randomisation algorithm
developed by Pocock and Simon17 to maintain a balance
between treatment arms with respect to study site,
number of exacerbations in the previous year, peripheral
blood eosinophils, BMI, total serum IgE, and treatment
dose. This method also helped to balance the distribution
of covariates that are known to be highly associated
with our primary endpoint (eg, number of previous
585 recruited

390 attended screening visit

55 did not meet inclusion criteria
22 blood eosinophils <150 cells per µL
16 inhaled corticosteroid dose too low
6 refused to consent or assent
4 fewer than two exacerbations in the previous year
3 required more than step-5 therapy
1 history of allergic reaction to biologic medication
1 no health insurance coverage
1 could not perform spirometry
1 pre-existing lung condition

335 enrolled and entered run-in period

45 discontinued study
17 lost to follow-up
13 did not meet randomisation criteria
9 other
6 withdrew consent or assent

290 randomly assigned

146 assigned to mepolizumab

144 assigned to placebo

20 terminated study
12 lost to follow-up
4 withdrew consent or assent
2 met exacerbation stopping
criteria
1 death
1 other

22 terminated study
16 lost to follow-up
4 withdrew consent or assent
1 met exacerbation stopping
criteria
1 investigator decision

126 completed study

122 completed study

146 included in the intention-to treat
analysis

144 included in the intention-to treat
analysis

Figure 1: Study design

504

exacerbations and peripheral blood eosinophils) and
covariates that determine if a participant fits the dosing
tables for omalizumab therapy approved by the US Food
and Drug Administration (FDA; eg, BMI and total serum
IgE; appendix pp 94–95). The criteria for exclusion
from randomisation included: participant could not
perform acceptable spirometry; participant did not have
documentation of medical insurance; and clinically
significant laboratory abnormality. Participants, investi
gators, research staff collecting outcome measures, and
data analysts remained masked to group assignments.
Unmasked pharmacists prepared the mepolizumab and
placebo syringes, which were identical in appearance.

Procedures
After screening, eligible participants were enrolled in a
4-week run-in period and study teams assumed the
management of participants’ asthma care according to a
guideline-based treatment algorithm.18 After the run-in
period, participants that met the randomisation criteria
were randomly assigned to adjunctive therapy with either
mepolizumab (6–11 years: 40 mg; 12–17 years: 100 mg) or
matching placebo, by subcutaneous injection once every
4 weeks for 52 weeks. Study outcomes and adverse events
were assessed at each study visit. Spirometry, impulse
oscillometry, and the measurement of fractional exhaled
nitric oxide (FeNO) were done according to American
Thoracic Society and European Respiratory Society
guidelines.19 Peripheral blood eosinophil counts were
determined by a central laboratory (Marshfield Hospital,
Marshfield, WI, USA), with the study team masked to
the results. Total serum IgE and specific IgE to
aeroallergens were quantified by a commercial laboratory
(Viracor, Lee’s Summit, MO, USA). Nasal lavage samples
were collected and processed for RNA sequencing using
a previously published protocol15 and analysed by study
investigators using a validated module analysis
framework (see appendix pp 2–6). The exacerbation
criterion for stopping study participation was initially
more than six exacerbations, modified to more than three
exacerbations on Jan 21, 2021 as an additional safety
measure.

Outcome measures
The primary outcome was the number of severe asthma
exacerbations treated with systemic corticosteroids
during the masked study treatment period. Systemic
corticosteroids were started after consultation with a
study-site clinician according to previously published
criteria (ie, albuterol needed for more than six individual
treatments in 24 h; moderate–severe wheeze, cough,
shortness of breath, or chest tightness or pain for at least
5 of the preceding 7 days; wheeze, cough, shortness of
breath, or chest tightness or pain severe enough to place a
participant in their red zone on their asthma action plan
that did not substantially improve after three doses of
albuterol; unscheduled visit for acute asthma care
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requiring repeated doses of albuterol; or hospitalisation
was needed for asthma).20 Secondary outcome measures,
not adjusted for multiplicity, included time to first asthma
exacerbation, changes in Composite Asthma Severity
Index (CASI) score,21 physician–patient global assessment
of response to therapy since starting the study, and lung
function (forced expiratory volume [FEV]1 % predicted).
Adverse events were identified by research staff via
observation, participant interview, or were self-reported
by the participant, and were collated by the research staff
from the time of participant consent to the end of their
participation in the study. Exploratory outcomes included
blood eosinophil counts, nasal lavage cell counts,
transcriptomics in relationship to the number of
exacerbations, and effects of treatment to modulate
immune inflammatory pathways.

Statistical analysis
The target sample size of 290 children (reduced from 320
because of lower drop-out than anticipated) provided
power of at least 0·9, with a two-sided type 1 error rate of
0·05 if the relative exacerbation rate ratio (RR) of the
mepolizumab versus placebo treatment was less than 0·6.
This calculation assumed an exacerbation rate of
1·2 events per year for the inferior treatment and allowed
for a 15% drop-out. The estimated RRs and corresponding
95% CIs for the primary and secondary analyses of
exacerbation rates were calculated using a negative
binomial model with an offset term that accounted for
per-participant follow-up time in the intention-to-treat
population. The model adjusted for randomisation
variables: study site, number of exacerbations in the year
before the study (2 vs ≥3), peripheral blood eosinophils
(<400 cells per μL vs ≥400 cells per µL), BMI
(<95th percentile vs ≥95th percentile), total serum IgE
(<540 kUA/L vs ≥540 kUA/L) and treatment dose (40 mg vs
100 mg). An interaction term was included when testing
the difference in RRs between participants who fitted the
omalizumab dosing table approved by the FDA, and those
who did not. To assess whether mepolizumab affected
exacerbation RR in relation to the omalizumab dosing
table approved by the FDA, we used the recommended
statistical test for interaction adjusted for the
randomisation variables described earlier.22 Secondary
outcome measures were not adjusted for multiplicity.23
We generated time to exacerbation survival function
estimates using the Kaplan–Meier method, and compared
survival curves by treatment group using a Cox regression
model adjusted for these covariates. Continuous secondary
and exploratory endpoints were estimated using a mixed
model for repeated measures (and a generalised additive
mixed model for exacerbation seasonality), which included
the treatment arm as a fixed effect, and adjusted for
randomisation variables, with weeks specified as an
unstructured covariance matrix for the repeated effects.
With a mixed model, no imputation of missing data was
required, as the estimates were unbiased according to the

All (n=290)

Mepolizumab
(n=146)

Placebo (n=144)

Demographic characteristics
Site
Boston

21 (7%)

11 (8%)

Chicago

26 (9%)

13 (9%)

13 (9%)

Cincinnati

31 (11%)

17 (12%)

14 (10%)

Dallas

36 (12%)

18 (12%)

18 (13%)

Denver

26 (9%)

13 (9%)

13 (9%)

Detroit

39 (13%)

19 (13%)

20 (14%)

New York

39 (13%)

19 (13%)

20 (14%)

St Louis

29 (10%)

14 (10%)

15 (10%)

Washington, DC

43 (15%)

22 (15%)

21 (15%)

10·0 (9·0–13·0)

10·0 (9·0–13·0)

10·5 (9·0–13·0)

Age, years

10 (7%)

Female

126 (43%)

71 (49%)

55 (38%)

Male

164 (57%)

75 (51%)

89 (62%)

Race
Black or African American

203 (70%)

106 (73%)

97 (67%)

White

31 (11%)

15 (10%)

16 (11%)

More than one race

26 (9%)

12 (8%)

14 (10%)

Unknown or not reported

27 (9%)

12 (8%)

15 (10%)

3 (1%)

1 (1%)

2 (1%)

Other
Ethnicity
Hispanic or Latino
Not Hispanic or Latino

72 (25%)

35 (24%)

37 (26%)

218 (75%)

111 (76%)

107 (74%)

Total monthly household income
<US$1250 per month

112 (39%)

54 (37%)

58 (40%)

100 (34%)

47 (32%)

53 (37%)

73 (25%)

42 (29%)

31 (22%)

5 (2%)

3 (2%)

2 (1%)

248 (86%)

123 (85%)

125 (88%)

82 (28%)

36 (25%)

46 (32%)

Weight, kg

47 (35–66)

46 (32–67)

48 (36–65)

BMI percentile

88 (63–98)

87 (64–98)

88 (61–98)

US$1251–2500 per month
>US$2501 per month
Unknown
Caretaker completed high school education
One or more smokers in the household
Clinical characteristics

52 (36%)

54 (38%)

Fractional exhaled nitric oxide, parts per
million

BMI greater than 95th percentile

34 (18–64)

29 (16–62)

35 (20–66)

FEV1% predicted

93 (17)

94 (16)

92 (18)

FEV1:FVC ratio
FEV1 % reversibility

106 (37%)

0·76 (0·09)
14 (13)

0·77 (0·09)
13 (11)

0·74 (0·10)
15 (15)

Any skin test positive
No

13 (4%)

4 (3%)

9 (6%)

Yes

263 (91%)

135 (92%)

128 (89%)

Missing data
Any allergen with IgE ≥0·35 kU/L
Total number allergens with IgE ≥0·35 kU/L

14 (5%)

7 (5%)

7 (5%)

277 (96%)

137 (94%)

140 (97%)

7 (4–11)

7 (4–11)

Eosinophils, cells per µL

430 (300–690)

7 (4–11)

400 (300–655)

455 (300–700)

Total serum IgE, kUA/L

404 (172–1008)

390 (170–914)

416 (174–1112)

(Table 1 continues on next page)

missing-at-random assumption.24 The interaction terms
of weeks and treatment were used to estimate the least
squares mean for each treatment group at each week, and
the difference in the least squares means was used to
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All (n=290)

Mepolizumab
(n=146)

6·9 (2·7)

6·9 (2·8)

Placebo (n=144)

(Continued from previous page)
Asthma characteristics
Composite Asthma Severity Index score

7·0 (2·6)

Treatment step
Step 3: fluticasone 250 µg twice a day

35 (12%)

18 (12%)

17 (12%)

Step 4: fluticasone 250 µg twice a day plus
long-acting β agonists

86 (30%)

38 (26%)

48 (33%)

Step 5: fluticasone 500 µg twice a day plus
long-acting β-agonists

169 (58%)

90 (62%)

79 (55%)

2

168 (58%)

86 (59%)

82 (57%)

3 or more

122 (42%)

60 (41%)

62 (43%)

2·8 (1·5)

2·7 (1·4)

2·8 (1·5)

Number of exacerbations in previous year

Number of oral steroids burst in the previous
year
Number of hospitalisations in the previous year
0

156 (54%)

74 (51%)

82 (57%)

1

80 (28%)

39 (27%)

41 (28%)

2

41 (14%)

26 (18%)

15 (10%)

3 or more

13 (4%)

7 (5%)

6 (4%)

Data are n (%), median (IQR), or mean (SD). FEV1=forced expiratory volume in 1 second. FVC=forced vital capacity.

Table 1: Baseline characteristics

compare mepolizumab and placebo. All analyses
presented are for the intention-to-treat population, clinical
analyses were done using SAS (version 9.4) and
mechanistic analyses using R (version 4.1.0). All figures
were constructed using R package ggplot2 (version 3.3.6).
Non-normally distributed data were log-transformed
before statistical analysis. Description of the methods
used in the nasal transcriptome analyses are provided
in the appendix (pp 2–6). The protocol was approved by
the NIAID Inner-City Asthma Consortium steering
committee, protocol review committee, data safety
monitoring board, and single institutional review board.
The statistical analysis plan is in the appendix (pp 98–138).
This trial is registered with ClinicalTrials.gov,
NCT03292588.

Role of the funding source
NIAID project scientists participated collaboratively in
the study design, data analysis and interpretation,
and the writing of the report. Study medication
(mepolizumab) was donated by GlaxoSmithKline, which
had the opportunity to comment on the study design but
had no role in data collection, analysis, or interpretation.

Results
This study was done between Nov 7, 2017, and
April 20, 2021. Between Nov 1, 2017, and Mar 12, 2020,
585 children and adolescents were recruited, of whom
390 (67%) attended a screening visit (figure 1). 55 people
did not meet the inclusion criteria and 335 did and were
enrolled. 45 of these participants discontinued the study
506

before being randomly assigned, including 13 who did not
meet the randomisation criteria. 290 participants were
randomly assigned to mepolizumab (n=146) or placebo
(n=144) groups. 42 participants terminated the trial early
after randomisation (mepolizumab n=20; placebo n=22).
Baseline characteristics were similar between treatment
groups; 43% were female, 70% were Black, 25% were
Hispanic, and 37% had a BMI in the 95th or higher
percentile (table 1). Asthma and type 2 inflammatory
characteristics included mean FEV1% predicted 93%,
FEV1:FVC ratio 0·76, FEV1% reversibility 14%, median
blood eosinophils 430 cells per µL, FeNO 34 parts per
billion, and total serum IgE 404 kUA/L. Baseline asthma
therapy was fluticasone 500 µg plus salmeterol 50 µg
twice daily or equivalent for 58% of participants, and the
mean number of oral corticosteroid courses in the year
before study entry was 2·8.
The primary outcome of the number of asthma
exacerbations that were treated with systemic
corticosteroids within the 52-week study period was
0·96 (95% CI 0·78–1·17) with mepolizumab vs
1·30 (1·08–1·57) with placebo (rate ratio 0·73 [0·56–0·96];
p=0·027; figure 2A).
The time to first asthma exacerbation was not
significantly different between treatment groups (hazard
ratio [HR] 0·86 [95% CI 0·63–1·18]; p=0·36; figure 2B).
There were no between-group differences in FEV1%
predicted, FEV1:FVC, or measures of impulse oscillometry
during the study (appendix p 7). The CASI improved
from baseline in both the mepolizumab and placebo
groups during study follow up; however, there was no
significant difference between treatment groups
(appendix p 8). Similarly, 109 (84%) of 129 patients in the
mepolizumab group and 110 (89%) of 124 in the placebo
group self-reported clinically moderate or significant
improvements in their asthma via the patient global
assessment12 at the end of study (odds ratio [OR] 0·72
[95% CI 0·42–1·24]; p=0·24; appendix p 13). Study
clinicians completed the same assessment and reported
clinically moderate or significant improve
ment in
85 (66%) of 129 participants in the mepolizumab group
and 87 (71%) of 122 in the placebo group (OR 1·01 [95% CI
0·62–1·64]; p=0·97; appendix p 13). When the
MUPPITS-2 study was designed, omalizumab was the
only approved biologic in children, so we included a
secondary analysis based upon whether participants met
FDA-approved omalizumab dosing criteria; the effect of
mepolizumab on exacerbation risk did not differ based
on whether participants fitted the omalizumab
FDA-approved dosing table or not (pinteraction 0·41). At the
end of the study, blood eosinophil counts were
significantly reduced in the mepolizumab group, with a
difference from baseline of –299 (95% CI –363 to –235;
p<0·0001), but remained unchanged in the placebo
group (appendix p 9). Nasal eosinophil percentage was
also significantly decreased in the mepolizumab group
(–13·4 [95% CI –20·5 to –6·3]; p=0·0003; appendix p 9),
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A

Exacerbation rate per participant year

2·0

Mepolizumab: rate 0·96
Placebo: rate 1·30
Rate ratio 0·73 (95% CI 0·56−0·96); p=0·027
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Placebo (n=144)
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Probability of remaining exacerbation−free

1·00

Placebo
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Hazard ratio 0·86 (95% CI 0·63−1·18); p=0·36
0
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(0)
Placebo 144
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although to a lesser extent than for blood eosinophils,
and unchanged in the placebo group. FeNO was not
significantly changed by therapy (appendix p 10).
As observed in previous studies in children,20,25,26 a posthoc analysis identified a strong seasonal exacerbation
pattern in the placebo group. This seasonal pattern was
significantly altered by mepolizumab (p=0·0006;
figure 2C), particularly with a blunting of the autumn
(fall) exacerbation peak (OR 0·64 [95% CI 0·42–0·98];
p=0·041).
Most (79·1%) of the study follow-up occurred before
the COVID-19 pandemic (appendix p 14). The overall
exacerbation rate was 58% lower during the COVID-19
pandemic; however, the relative reduction in the
exacerbation rate observed with mepolizumab was not
different before versus during the pandemic.
Mepolizumab treatment was generally well tolerated;
there were modest between-group differences in the
adverse events reported by participants, except for higher
rates of injection-site reactions associated with
mepolizumab than with placebo (table 2). Five episodes
of anaphylaxis occurred (mepolizumab n=3, placebo
n=2), none of which was related to study therapy. One
death occurred in the mepolizumab group during the
trial owing to an acute, severe asthma exacerbation
leading to cardiopulmonary arrest.
In prespecified exploratory analyses, nasal lavage RNAsequencing at baseline (week 0) and end of study
(week 52) was used to identify molecular patterns
associated with exacerbation risk and treatment
responses. Whole genome transcriptome data were
summarised using a previously defined and validated
repertoire of 52 cell-associated nasal gene networks
(modules), a subset of which were previously linked to
risk for asthma exacerbations in urban children
(appendix pp 15–16).15 Multivariate partial least squares
regression identified 12 (23%) of 52 modules for which
expression values at baseline were related to exacerbation
numbers during the course of the study in the placebo, or
mepolizumab, or both, treatment groups (figure 3).
Univariate negative binomial modelling of exacerbation
rates as a function of baseline module expression yielded
similar results (table 3; appendix p 11).
Baseline expression values of three eosinophilassociated modules functionally representative of
type 2 inflammation, eicosanoid metabolism, and
cytoplasmic proteins were associated with increased
exacerbation risk in participants treated with placebo, but
not mepolizumab. Rate ratios (RRs), representing the
estimated exacerbation RR for a doubling of module
expression ranged from 1·25–1·74 in the placebo
group (p=0·0012–0·015; table 3). Furthermore, these
three modules were significantly downregulated by
mepolizumab from week 0 to week 52 (figure 3;
appendix p 17; fold changes 0·77–0·90; p=0·00017–0·011),
whereas these modules remained unchanged in the
placebo group (p>0·05).

Time (month)

Figure 2: Effect of mepolizumab on asthma exacerbations
(A) Asthma exacerbations with error bars showing 95% CIs. (B)T ime to first
asthma exacerbation. (C) Post-hoc analysis of the seasonal pattern of asthma
exacerbation, with 95% CIs shown by red or blue shading and autumn months
shown by grey shading.
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By contrast, baseline expression of five epithelialassociated modules was significantly related to
exacerbation risk in the mepolizumab group, but not in
the placebo group (RR 1·24–1·41; p=0·0035–0·030); these
modules represent multiple functional and inflammatory
pathways of the epithelium including keratinisation and
tight junctions, epidermal growth factor receptor (EGFR)
signalling and cell–cell adhesion, IL-33 response and cilia
Mepolizumab
(n=146)

Placebo
(n=144)

Any treatment-emergent adverse
event

42/146 (29%)

16/144 (11%)

Injection site reactions

19/146 (13%)

7/144 (5%)

Skin and subcutaneous tissue disorders 10/146 (7%)

1/144 (<1%)

Gastrointestinal disorders

7/146 (5%)

3/144 (2%)

Changes in laboratory values or vital
signs

5/146 (3%)

3/144 (2%)

Nervous system disorders
(eg, headache, dizziness, and syncope)

7/146 (5%)

0/144 (0%)

Data are n/N (%). The table shows adverse events with an overall incidence of
more than 3%.

Table 2: Adverse events related to study treatment

function, extracellular matrix production, and induction
of tissue kallikreins and IL-23 and IL-17 pathway signalling.
A sixth epithelial module identified by partial least
squares regression, labelled transforming growth factor β
(TGF-β)/Smad3 associated cell differentiation, showed a
similar trend (RR 1·36; p=0·077). Five of these six
modules were significantly upregulated by mepolizumab
therapy (fold changes 1·25–1·37, p=0·0002–0·0089); all
were unchanged by placebo.
Uniquely, one module related to eosinophil activation
and mucus hypersecretion (linked to both eosinophils
and the epithelium) was positively associated
with exacerbation risk in both treatment groups
(RR 1·20–1·29; p=0·014–0·039) and was unchanged by
therapy. Two modules related to type 1 interferon
regulation and neutrophil chemotaxis were inversely
associated with exacerbations in both groups
(RR 0·70–0·76; p=0·0099–0·062) and were unchanged
by therapy.
In addition to providing important mechanistic
information, the nasal module expression values more
accurately defined exacerbation risk and distinguished
treatment effects than previously studied biomarkers
including nasal cell percentages, blood eosinophils,

Relationship between nasal gene
module expression at week 0 and
the number of exacerbations during
weeks 0–52

Module cell association

Module annotation

Mepolizumab

Placebo

Eosinophil

Type 2 inflammation

↓†

ns

Eicosanoid metabolism

↓‡

ns

Eosinophil and epithelium
Epithelium

Treatment effect
Expression change from
week 0 to week 52

Cytoplasmic proteins

↓*

ns

Activation, mucus secretion

ns

ns

Keratinisation, tight junctions

↑†

ns

EGFR signalling, cell–cell adhesion

↑‡

ns

Cilia function, IL-33 response

ns

ns

Extracellular matrix production

↑†

ns

TGF-β/Smad3 cell differentiation

↑‡

ns

Tissue kallikreins, IL-23 and IL-17 pathway

↑†

ns

Neutrophil chemotaxis

ns

ns

Type 1 interferon regulation

ns

ns

Neutrophil

Mepolizumab treatment group
Placebo treatment group

–0·5

0

0·5

Lower exacerbation rate Higher exacerbation rate

Figure 3: Nasal gene module expression and exacerbation rates and treatment
12 gene-expression modules, measured from nasal lavage at the randomisation visit (week 0), showed significant relationships to the primary clinical outcome of the
number of exacerbations during the study in either the placebo group, or the mepolizumab group, or both, by multivariate partial least squares regression. The figure
shows the weights for each of the 12 modules and for each treatment group, with the weight value shown for the placebo group and the mepolizumab group.
A positive weight (with the bar to the right of the centre) indicates a positive association with the number of exacerbations, whereas a negative weight (with the bar
to the left of the centre) indicates an inverse association. Weight values can range from 0 to 1 and partly reflect the relative importance of each module in the
modelling exacerbation number. Eight of the 12 modules showed differential expression from week 0 to week 52 in the mepolizumab group, whereas no modules
were differentially expressed from week 0 to week 52 in the placebo group. Downward arrows indicate a decrease in expression, whereas upward arrows indicate an
increase. For further details about each module see the appendix (p- 15–16). EGFR=epidermal growth factor receptor. ns=no significant change in expression.
IL=interleukin. TGF-β=transforming growth factor β. *p<0·05. †p<0·01. ‡p<0·001.
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pulmonary functions, and FeNO (appendix p 18).
Although nasal eosinophils were numerically related to an
increased exacerbation risk in the placebo group, and
nasal epithelial cells were related to an increased
exacerbation risk in the mepolizumab group, neither
relationship was statistically significant. Furthermore,
the eosinophil-associated eicosanoid metabolism and
cytoplasmic protein modules remained significantly
associated with exacerbation numbers in the placebo
group after adjustment for cell percentage (p<0·05); only
the type 2 inflammation module did not retain significance
independent of cell percentage (p=0·26). Similarly, the
epithelial-associated keratinisation and tight junctions,
EGFR signalling and cell–cell adhesion, IL-33 and cilia
production, and extracellular matrix production modules
remained significantly associated with the exacerbation
number in the mepolizumab group after adjustment for
cell percentage (p<0·05); the tissue kallikreins IL-23 and
IL-17 pathway module did not retain significance adjusted
for cell percentages (p=0·12). Blood eosinophils (appendix
p 12), FEV1% predicted, and FeNO did not show significant
relationships with exacerbations rates, although lower
FEV1:FVC percent predicted related to higher exacerbation
rates in both groups (appendix p 18).

Discussion
Phenotype-directed therapy with mepolizumab added to
guideline-based care reduced the number of recurrent
exacerbations in urban children aged 6–17 years with
eosinophilic exacerbation-prone asthma. We did not
observe significant between-treatment differences in
lung function as assessed by spirometry or impulse
oscillometry, CASI scores, or physician–patient global
assessments. There were improvements in asthma
control both in participants treated with mepolizumab
and those treated with placebo, high
lighting the
effectiveness of interventions associated with clinical
trials that promote adherence to guideline-based care in
children at high-risk.
Our
incorporation
of
longitudinal
nasal
transcriptomic analyses to more precisely characterise
mepolizumab treatment responsiveness than in the
past provided an advancement in the understanding of
mepolizumab’s effects on asthma exacerbations. These
analyses provided crucial insights into the mechanisms
underlying the response to mepolizumab therapy
and identified those inflammatory pathways that
contribute to exacerbations despite reducing eosinophilrelated inflammation. As anticipated, higher baseline
expression of inflammatory pathways involving the
eosinophil, inclusive of canonical type 2 inflammation
and eicosanoid metabolism, and eosinophil cytoplasmic
proteins, identified risk for more exacerbations in the
placebo group compared with the mepolizumab group.
However, components of eosinophil activation that
were associated with airway mucus hypersecretion
persisted, despite mepolizumab therapy, and were

Module annotation

Mepolizumab (n=125)

Placebo (n=124)

RR

p value

RR

p value

Eosinophil

Type 2 inflammation

1·10 (0·89–1·35)

0·36

1·25 (1·05–1·5)*

0·015

Eosinophil

Eicosanoid
metabolism

1·15 (0·84–1·57)

0·37

1·62 (1·21–2·2)*

0·0012

Eosinophil

Cytoplasmic proteins

1·19 (0·77–1·82)

0·42

1·74 (1·21–2·52)*

0·0027

Eosinophil and
epithelium

Activation, mucus
secretion

1·29 (1·06–1·58)*

0·014

1·20 (1·00–1·44)*

0·039

Epithelium

Keratinisation, tight
junctions

1·32 (1·09–1·61)*

0·0053

1·11 (0·90–1·39)

0·30

Epithelium

EGFR signalling cell–
cell adhesion

1·34 (1·10–1·64)*

0·0049

1·10 (0·90–1·36)

0·31

Epithelium

Cilia function, IL-33
response

1·25 (1·04–1·51)*

0·020

1·11 (0·92–1·33)

0·24

Epithelium

Extracellular matrix
production

1·41 (1·12–1·77)*

0·0035

1·06 (0·86–1·32)

0·58

Epithelium

TGF-β/Smad3 cell
differentiation

1·36 (0·98–1·89)

0·077

1·04 (0·74–1·45)

0·83

Epithelium

Tissue kallikreins,
IL-23 and IL-17
pathway

1·24 (1·02–1·51)*

0·030

1·03 (0·81–1·31)

0·82

Neutrophil

Neutrophil
chemotaxis

0·72 (0·51–1·02)

0·062

0·70 (0·51–0·94)*

0·011

Neutrophil

Type 1 interferon
regulation

0·76 (0·58–1·00)*

0·050

0·74 (0·58–0·95)*

0·0099

Data are RR (95% CI). Results of negative binomial regression of exacerbation number compared with baseline nasal
lavage module expression on a log2 scale for each module depicted in figure 2. RRs represent the estimated rate ratio
for a one-unit increase in log2 module expression (ie, a doubling of expression). Modules are listed by their cell
association and annotation. For further details about each module see the appendix (p 10). RR=rate ratio.
EGFR=epidermal growth factor receptor. IL=interleukin. TGF-β=transforming growth factor β. *p≤0·05.

Table 3: Baseline module expression and exacerbation rates

associated with a continued exacerbation risk. These
observations suggest that despite mepolizumab’s
overall reduction in eosinophil numbers and type 2
inflammation, refractory mechanisms of eosinophils
and epithelium-regulating mucins contri
bute to
exacerbation risk and incomplete responses to
mepolizumab. Indeed, our previous work identified
this pathway as key to asthma exacerbation progression
and lower lung function.15,27,28 Similarly, mucus
overproduction has been established as having a key
role in severe asthma in adults29,30 and is only partially
related to airway eosinophil numbers.
A novel observation of our study was that elevated
baseline expression of multiple non-type 2 inflammatory
pathways from the epithelium identified risk for
exacerbations in the mepolizumab group, and expression
of many of these pathways increased while on
mepolizumab therapy. These epithelial pathways have
been identified previously15,31 as underlying aspects of
both viral and pollution triggered exacerbations in urban
children and can occur independent of type 2
inflammation. These observations suggest that when
type 2 inflammation is dampened with mepolizumab,
epithelial inflammatory pathways can promote disease
activity and might even show reciprocal elevation.
Furthermore, adverse environmental exposures in urban
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children driving these epithelial inflammatory pathways
might partially account for the small therapeutic
response observed in this population.
Additionally, these findings highlight the complexity of
treating heterogeneous inflammatory pathways that exist
in asthma, even among individuals meeting accepted
criteria for an eosinophilic phenotype, and might help
explain the persistent risk for exacerbations, albeit at
lower rates, observed across studies of biologics that
target type 2 inflammation. Perhaps most importantly,
our results highlight key molecular pathways that can be
considered for future interventional strategies, such as
mucus hyper
secre
tion, the kallikrein-kinin system,
extracellular matrix overproduction, EGFR signalling,
and TGF-β/Smad3 signalling. Our data also highlight
the need to tailor therapies towards each individual’s
airway inflammatory profile, including the potential
importance of targeting multiple inflammatory pathways,
or their proximal drivers, or both.
Post-hoc analyses identified significant seasonal
variation in exacerbations with the most prominent
mepolizumab treatment effect in the fall. The overall
effects of mepolizumab therapy on exacerbations were
more modest than expected despite similar substantial
reductions in blood eosinophils to those in previous
mepolizumab trials in adults and children,11,32 and also
significant reductions in nasal airway eosinophils
(although to a lesser extent than in blood). In contrast to
our study, previous trials done in adults had low
numbers of Black and Hispanic participants.
Importantly, the social and environmental determinants
of health facing disadvantaged urban Black and Hispanic
children are unique relative to populations studied in
previous mepolizumab trials. Furthermore, the pathways
driving type 2-high, eosinophilic asthma might differ
between children and adults. For example, adult
participants with childhood-onset versus adult-onset
eosinophilic asthma have been less responsive to
benralizumab, another biologic therapy targeting IL-5.16,33
Our findings also raise the possibility that exacerbations
in adults are more commonly driven by eosinophils,
whereas in children, other inflammatory processes are
instrumental.
The strengths of our study include a diverse range of
participants who were at greatest risk of asthma morbidity,
predominantly Black and Hispanic children living in
disadvantaged urban communities, an understudied
population. Another study strength was the high retention
and adherence to injections despite a portion of the trial
occurring during the COVID-19 pandemic. Furthermore,
integration of airway transcriptomic network analyses
into this multisite paediatric clinical trial enabled the
identification of novel mechanisms of response and nonresponse to mepolizumab therapy.
A study limitation is the use of nasal airway samples as
a proxy for lower airway disease; however, this issue is
mitigated by the direct relevance of these pathways to
510

asthma outcomes.15,34,35 The COVID-19 pandemic affected
the frequency of asthma exacerbations; however, this did
not significantly affect the observed treatment effects of
mepolizumab.
In conclusion, in urban children and adolescents
with exacerbation-prone eosinophilic asthma, adjunctive
therapy with mepolizumab reduced asthma exacer
bations, but did not affect other asthma outcomes.
Airway transcriptomic analyses identified primarily
eosinophil-associated and epithelial-associated molecular
pathways underlying differential clinical responses to
mepolizumab and identified potential future targets to
precisely and effectively diminish disease burden from
exacerbations in these youth at high risk. Our findings
also highlight the importance of evaluating treatment
responses for biologics, and other interventions, in urban
Black and Hispanic children, populations often underrepresented in clinical trials and at greatest risk for
morbidity and mortality from asthma.
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